Diabetes-related exclusion criteria included: type 1 diabetes; diabetes insipidus; corticosteroid-induced type 2 diabetes; a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma; poorly controlled diabetes characterized by polyuria/polydipsia with >10% weight loss; use of insulin within 1 year of enrolment, except in the case of hospitalization or use in gestational diabetes.
Supplementary

OAD, oral antidiabetic drug
Sample size calculations To demonstrate non-inferiority of dapagliflozin in comparison with glipizide as add-on therapy to metformin for changes from baseline to week 52 in HbA1C with a non-inferiority margin of 0.35 %, assuming a standard deviation (SD) of 1.25 %, and at a one-sided significance level of 0.025, 280 evaluable patients were needed in each treatment group to provide approximately 90% power (given a true difference of zero between the 2 treatment groups). Assuming a 5% exclusion rate from the full analysis set, 295 patients per treatment group are needed for the full analysis set. Additionally, to have 90% power for the per-protocol population and assuming a 25% exclusion rate from the per-protocol population, 373 patients per treatment group (746 patients in total) were planned for randomization. HbA1C, percent, mean ± SD 7.7 ± 0.9 7.7 ± 0.9 FPG, mmol/L, mean ± SD 9.0 ± 2.1 9.1 ± 2.3
Supplementary
Fasting C-peptide, nmol/L, mean ± SD 1.00 ± 0.43 0.95 ± 0.44 OAD use at enrolment*, n (%) Data are mean (standard deviation) or mean [standard error]; x=number of patients with orthostatic hypotension at baseline or week 52 defined as decrease from supine to standing of >20 mm Hg in systolic blood pressure or >10 mm Hg in diastolic blood pressure. n=number of patients with nonmissing baseline or week 52 values in the safety analysis set.*Calculated using the Cockcroft-Gault equation (14) with current values for body weight at each study visit; †Calculated post hoc using baseline body weight for all study visits. The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 5 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed *We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, nonpharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org
